Roche's CDx gets FDA approval for use with Tecentriq

2021-10-25

Roche's VENTANA PD-L1 (SP263) Assay has been approved by the FDA for use as a companion diagnostic to identify patients with non-small cell lung cancer who may be treated with Tecentriq, or atezolizumab. "With the FDA approval of this companion diagnostic test, clinicians now have an effective tool for offering better patient care through targeted immunotherapy treatment," said Roche Diagnostics CEO Thomas Schinecker.

Full story:

AdvaMed SmartBrief

Medical devices, health care information systems and diagnostic products

Designed specifically for manufacturers of medical devices, health care information systems and diagnostic products, AdvaMed SmartBrief is a FREE e-mail newsletter. By providing a summary of the day's most important medical technologies news, AdvaMed SmartBrief saves you time and keeps you smart.